The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | CAR-T expansion is associated with treatment response, CRS, and cytopenia in patients with R/R MM
Maximilian Merz, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses a study utilizing flow cytometry to analyze responses to CAR T-cell therapies in patients with relapsed/refractory (R/R) multiple myeloma (MM). The findings indicate a correlation between CAR-T expansion and treatment response, though this association is accompanied by the increased occurrence of cytokine release syndrome (CRS) and prolonged cytopenia. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Amgen, Takeda, BMS, Janssen, Stemline, Roche
